 Home > Active Ingredient News > Immunology News > J Clin Rheumatol: Is there an increased risk of infection in patients with rheumatoid arthritis using JAK inhibitors?

J Clin Rheumatol: Is there an increased risk of infection in patients with rheumatoid arthritis using JAK inhibitors?

 Last Update: 2022-05-14
 Source: Internet
 Author: User

Tags

adp receptor inhibitors

wound infection treatment

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Rheumatoid arthritis is an autoimmune, chronic and inflammatory disease that affects approximately 5 out of every 1,000 adults worldwide

We searched PubMed, EMBASE, the Cochrane Library and clinicaltrials.

RESULTS: A total of 37 randomized controlled trials were included in the study

Taken together, the findings of this study suggest that the risk of infection is similar among currently approved JAK inhibitor drugs

Original source:

Carlos Alves, et al.

leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Top Product

$10-13/UNIT FOB

Thymulin 63958-90-7 OUDA

CAS No.: 63958-90-7

Pharmacy Grade

$2.5-3/KG FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.